Group 1 - The stock price of Qianxin Biopharmaceuticals-B (02509) has risen over 8% during trading, reaching a new high of 22.15 HKD, marking a nearly 40% increase in the past month [1] - Qianxin Biopharmaceuticals focuses on biopharmaceuticals for autoimmune and allergic diseases, with a fully self-developed drug pipeline and mature commercial-scale production capabilities [1] - The company has a diverse product pipeline, including one product approved for market, two in Phase III clinical trials, and four in Phase II and I trials, targeting diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease [1] Group 2 - In April, Qianxin Biopharmaceuticals signed a licensing agreement with Caldera Therapeutics for its clinical-stage long-acting dual antibody QX030N, granting Caldera global exclusive rights for development and commercialization [2] - The agreement includes a one-time payment of 10 million USD, approximately 24.88% equity in Caldera, and potential additional payments up to 545 million USD along with tiered royalties on net sales [2] - The company anticipates that its biosimilar product, Sailixin, will enter the medical insurance directory in 2024, with projected sales of 300 million CNY in 2025 and peak sales of 1.5 billion to 2 billion CNY, contributing to the company's revenue through profit sharing [2]
荃信生物-B盘中涨超8% 近一个月股价累涨近四成 自免双抗布局国内领先